Form 4 for ALNY ALNYLAM PHARMACEUTICALS, INC.
Accepted 2021-08-16 00:00:00 ET · period of report 2021-08-13 · accession 0001735276-21-000083 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-08-16 | 2021-08-13 | ALNY | MARAGANORE JOHN | CEO, Dir | S - Sale+OE | $199.78 | -34.0K | 218.8K | -13% | -$6.79M |
| D | 2021-08-16 | 2021-08-13 | ALNY | MARAGANORE JOHN | CEO, Dir | M - OptEx | $7.10 | +34.0K | 248.7K | +16% | +$241.3K |
| D | 2021-08-16 | 2021-08-13 | ALNY | MARAGANORE JOHN | CEO, Dir | M - OptEx | $0.00 | -34.0K | 34.0K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-08-13 | S | D | 2,441 | $198.02 | 246,303 | D | — | — | (F2) Sale prices ranged from $197.44 to $198.44. |
| 2 | Common | Common Stock | 2021-08-13 | S | D | 4,160 | $198.93 | 242,143 | D | — | — | (F3) Sale prices ranged from $198.45 to $199.44. |
| 3 | Common | Common Stock | 2021-08-13 | S | D | 3,828 | $200.84 | 214,979 | D | — | — | (F5) Sale prices ranged from $200.48 to $201.43. |
| 4 | Common | Common Stock | 2021-08-13 | S | D | 214 | $201.55 | 214,765 | D | — | — | |
| 5 | Common | Common Stock | 2021-08-13 | M | A | 33,979 | $7.10 | 248,744 | D | — | — | |
| 6 | Common | Common Stock | 2021-08-13 | S | D | 23,336 | $199.92 | 218,807 | D | — | — | (F4) Sale prices ranged from $199.46 to $200.45. |
| 7 | Derivative | Stock Option (right to buy) | 2021-08-13 | M | D | 33,979 | $0.00 | 33,978 | D | $7.10 · — to 2021-11-30 | 33,979 Common Stock | (F7) The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. |